Get Started in Minutes
How Xembify Copay Assistance Works
1 – Check Your Coverage/Benefits Verification
Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.
2 – Transfer Prescription to AmeriPharma
We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.
3 – Prior Authorization
Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.
4 – Xembify Copay Assistance & Financial Aid
We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma Specialty Care has secured $55 million in financial assistance for our patients.
5 – Nursing Care Coordination
AmeriPharma puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.
6 – Delivery Coordination
Medications are always delivered in strict compliance with the specific requirements for immune globulin shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.
What Is Xembify?
Xembify is a type of subcutaneous immunoglobulin (SCIG). It contains a broad spectrum of antibodies (immune globulins) extracted from a large pool of human plasma.
Xembify is a 20% immune globulin solution that is FDA indicated for primary humoral immunodeficiency and can be used in a number of other medical conditions.
How Does Xembify Work?
Xembify provides a variety of immunoglobulins (Ig) that are opsonizing (more easily destroyed) and neutralizing in nature. Bacteria, viruses, parasites, and mycoplasmal agents and the toxins they release are neutralized by the antibodies found in Xembify.
What Is Xembify Used To Treat?
Xembify is FDA-indicated for primary humoral immunodeficiency in patients 2 years of age and older. This includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
Primary Humoral Immunodeficiency (PI)
The suboptimal function of the immune system in a primary humoral immunodeficiency patient can be detrimental. Treatment with Xembify can greatly strengthen the immune system and improve the quality of life.
Warnings of Xembify Usage
Upon evaluation, your doctor will determine if Xembify is ideal for you. Inform your doctor if you:
- Have cardiovascular (heart) problems
- Suffer from hyperviscosity (thickness) of blood from a sedentary lifestyle
- Have a permanent IV catheter placed
- Are taking any medications that contain estrogen
- Have renal (kidney) impairment
- Have risk factors of thrombosis
Patients with the risk of thrombosis should be treated with extra caution. In such cases, the doctor may prescribe Xembify at a minimum dose and a lower infusion rate.
Copay and Financial Assistance
AmeriPharma Specialty Care alleviates financial burdens for patients and their families
Advanced software locates funding sources to match you with top-dollar foundation programs
One of our copay assistance specialists will assist with the application process
Automatic updates will be sent to you and your physician on the status of the funding
Xembify Warnings and Precautions
Serious side effects include:
- Hypersensitivity reactions
- Aseptic meningitis syndrome (AMS)
- Renal failure and hemolysis
- Transfusion-related acute lung injury (TRALI)
- Interference with lab tests
- Transmission of infectious agents
Non-serious side effects:
- Infusion site erythema (redness)
- Infusion site pain
- Infusion site swelling
- Infusion site bruising
- Infusion site pruritus (itching)
- Infusion site induration (firmness)
- Infusion site scab
- Infusion site edema
- Systemic reactions (e.g., cough and diarrhea)
A patient’s pharmacokinetics and clinical response determine the dose of Xembify. The following sequence is adopted to determine the right amount.
- After initiating Xembify treatment, measure the serum IgG trough level of the patient as early as 5 weeks.
- Continue monitoring IgG trough level every 2 to 3 months to determine if any subsequent dose adjustments are needed.
- For frequent dosing (i.e., two to seven times per week), divide the calculated weekly dose by the desired number of infusions per week.
Note: If a patient does not maintain adequate clinical response to Xembify therapy (or serum IgG level is not achieved to the level of a previous treatment), dose adjustments may be necessary. For dose adjustments, the doctor will calculate the difference of the IgG trough level from the target IgG trough level, then find the difference via the following table:
Dose Adjustment (ML per Week)
|Difference from Target IgG trough level (mg/dl)||10kg||15kg||20kg||30kg||40kg||50kg||60kg||70kg||80kg||90kg||100kg||110kg||120kg|
Locate the corresponding amount (in ml) by which to increase/decrease the weekly dose based on the patient’s body weight.
Example: If a patient with a body weight of 70 kg has IgG trough level of 900 mg/dl and the target level is 1000mg/dl, the difference is 100mg/dl. Thus, increase the weekly dose by 5 ml.